Clinical Trial Update: RFA or Surgical Resection Combined With Neo-MASCT for Primary HCC: a Phase II Trial [Phase 2]

View source ↗

Summary

Phase II trial evaluating RFA or surgical resection combined with Neo-MASCT for primary hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Liver Cancer

Snippet

Sponsor: Sun Yat-sen University | Conditions: Primary Liver Cancer, Radiofrequency Ablation | Phase 2 | Status: UNKNOWN